Loading clinical trials...
Loading clinical trials...
A Phase 3 Double-blind, Randomized, Placebo-controlled, Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Fibromyalgia (Protocol A0081245)
Conditions
Interventions
pregabalin
placebo
Locations
52
United States
Andrew O. Schreiber, MD
Orange, California, United States
Apex Research Institute
Santa Ana, California, United States
Paddock Park Clinical Research
Ocala, Florida, United States
Broward Research Group
Pembroke Pines, Florida, United States
Meridien Research
Tampa, Florida, United States
Arthritis Care Center
Moline, Illinois, United States
Start Date
March 1, 2011
Primary Completion Date
July 1, 2012
Completion Date
July 1, 2012
Last Updated
January 22, 2021
NCT05901259
NCT03759522
NCT07186751
NCT06574165
NCT06157866
NCT05067998
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions